PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model

BACKGROUND: Blockade of PD-1 receptor may provide proof of concepts for the activity of an immune-modulation approach for the treatment of breast cancer (BC). Zoledronic acid (ZA) has been proven to inhibit angiogenesis, invasion, and adhesion of tumor cells. The aim of this study was to investigate...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yuan, Du, Yang, Sun, Ting, Xue, Huadan, Jin, Zhengyu, Tian, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6009040/
https://www.ncbi.nlm.nih.gov/pubmed/29921237
http://dx.doi.org/10.1186/s12885-018-4412-8
_version_ 1783333303963615232
author Li, Yuan
Du, Yang
Sun, Ting
Xue, Huadan
Jin, Zhengyu
Tian, Jie
author_facet Li, Yuan
Du, Yang
Sun, Ting
Xue, Huadan
Jin, Zhengyu
Tian, Jie
author_sort Li, Yuan
collection PubMed
description BACKGROUND: Blockade of PD-1 receptor may provide proof of concepts for the activity of an immune-modulation approach for the treatment of breast cancer (BC). Zoledronic acid (ZA) has been proven to inhibit angiogenesis, invasion, and adhesion of tumor cells. The aim of this study was to investigate the potential of monoclonal antibody against T cell checkpoint PD-1 in combination with chemotherapeutic drug ZA in BC mouse model. METHODS: The 4 T1-fLuc mouse BC model was used in this study. The anti-tumor efficacy of anti-PD-1 antibody alone or in combination with ZA was monitored by measuring bioluminescence imaging (BLI) and tumor volume. At the end of study, the flow cytometry was used to determine the immune cell population in tumors after different treatment. RESULTS: The results showed that mice treated with the combination therapy of anti-PD-1 antibody plus ZA exhibited better antitumor response compared to untreated controls or single therapy with no obvious toxicity. CONCLUSION: Our study provides preclinical evidence for the enhanced BC treatment benefit through targeting co-signal molecules by combining anti-PD-1 antibody plus ZA treatment.
format Online
Article
Text
id pubmed-6009040
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-60090402018-06-27 PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model Li, Yuan Du, Yang Sun, Ting Xue, Huadan Jin, Zhengyu Tian, Jie BMC Cancer Research Article BACKGROUND: Blockade of PD-1 receptor may provide proof of concepts for the activity of an immune-modulation approach for the treatment of breast cancer (BC). Zoledronic acid (ZA) has been proven to inhibit angiogenesis, invasion, and adhesion of tumor cells. The aim of this study was to investigate the potential of monoclonal antibody against T cell checkpoint PD-1 in combination with chemotherapeutic drug ZA in BC mouse model. METHODS: The 4 T1-fLuc mouse BC model was used in this study. The anti-tumor efficacy of anti-PD-1 antibody alone or in combination with ZA was monitored by measuring bioluminescence imaging (BLI) and tumor volume. At the end of study, the flow cytometry was used to determine the immune cell population in tumors after different treatment. RESULTS: The results showed that mice treated with the combination therapy of anti-PD-1 antibody plus ZA exhibited better antitumor response compared to untreated controls or single therapy with no obvious toxicity. CONCLUSION: Our study provides preclinical evidence for the enhanced BC treatment benefit through targeting co-signal molecules by combining anti-PD-1 antibody plus ZA treatment. BioMed Central 2018-06-19 /pmc/articles/PMC6009040/ /pubmed/29921237 http://dx.doi.org/10.1186/s12885-018-4412-8 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Li, Yuan
Du, Yang
Sun, Ting
Xue, Huadan
Jin, Zhengyu
Tian, Jie
PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model
title PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model
title_full PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model
title_fullStr PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model
title_full_unstemmed PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model
title_short PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model
title_sort pd-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6009040/
https://www.ncbi.nlm.nih.gov/pubmed/29921237
http://dx.doi.org/10.1186/s12885-018-4412-8
work_keys_str_mv AT liyuan pd1blockadeincombinationwithzoledronicacidtoenhancetheantitumorefficacyinthebreastcancermousemodel
AT duyang pd1blockadeincombinationwithzoledronicacidtoenhancetheantitumorefficacyinthebreastcancermousemodel
AT sunting pd1blockadeincombinationwithzoledronicacidtoenhancetheantitumorefficacyinthebreastcancermousemodel
AT xuehuadan pd1blockadeincombinationwithzoledronicacidtoenhancetheantitumorefficacyinthebreastcancermousemodel
AT jinzhengyu pd1blockadeincombinationwithzoledronicacidtoenhancetheantitumorefficacyinthebreastcancermousemodel
AT tianjie pd1blockadeincombinationwithzoledronicacidtoenhancetheantitumorefficacyinthebreastcancermousemodel